May 6, 2025
| Today’s news and insights for biopharma leaders
Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing obstacle to large acquisitions.
|
UPDATED
While deals announced by Merck KGaA and Novartis provided a small M&A spark, big pharma buyers appear to be favoring a “wait-and-see” approach as they sort out broader policy uncertainty.
|
Yet regulatory relief for U.S. expansion could be accompanied by new tariffs and drug pricing rules.
|
Flexible supply chain models with on-demand packaging to support patient-focused clinical supply, based on actual site and patient demand.
|
News roundup
Bluebird urged shareholders to back a take-private deal that could close imminently. Elsewhere, Unity Biotechnology began a strategic review and Mersana announced plans to cut more than half its workforce.
|
|
Stronger connections lead to better outcomes. In this infographic, learn how to use key moments in the product lifecycle, from drug discovery to commercialization, to help transform patient care.
|
|
From Our Library
Trendline
Supported by Phil Inc
|
Trendline
Supported by EVERSANA
|
Trendline
Supported by Catalent
|
Infographic
Custom content for WCG
|
Playbook
Custom content for Premier Research
| | 
